Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

Last Updated: Tuesday, March 11, 2025

A retrospective observational study evaluated real-world treatment patterns and outcomes among 317 patients with metastatic HR+ HER2- breast cancer who were treated with first-line palbociclib plus fulvestrant. The researchers concluded that the data suggest favorable real-world outcomes among patients treated with this combination.

Future Oncology

Journal of Clinical Oncology

Single center study of efficacy and safety of capivasertib in hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC)

Science Progress

Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence

Journal of Clinical Oncology

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study

American Medical Journal

Updates in advanced hormone receptor-positive breast cancer: From circulating tumor DNA-guided therapy to precision medicine

Annals of Oncology

Overall survival with abemaciclib in early breast cancer

Journal of Clinical Oncology

Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

HR+ HER2- Breast Cancer Resource Center

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

Journal of Clinical Oncology

Single center study of efficacy and safety of capivasertib in hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC)

Science Progress

Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence

Journal of Clinical Oncology

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study

American Medical Journal

Updates in advanced hormone receptor-positive breast cancer: From circulating tumor DNA-guided therapy to precision medicine

Annals of Oncology

Overall survival with abemaciclib in early breast cancer

Journal of Clinical Oncology

Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

Navigating Treatment Adherence in Early-Stage Breast Cancer

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer